Olanzapine and Olanzapine Pamoate

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.018

15 - Olanzapine and Olanzapine Pamoate

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

Olanzapine is among the more extensively studied second-generation antipsychotics (SGAs), partly due to its approval 25 years ago (1996), and also due to its penchant for significant metabolic adverse effects [9, 10]. Olanzapine distinguished itself by its efficacy profile (Figure 15.1), combined with lower rates of hyperprolactinemia and neurological adverse effects than first-generation antipsychotics (FGAs) and risperidone [11]. In the US Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, the primary outcome measure was time to all-cause discontinuation, and olanzapine outperformed other antipsychotics in phase 1 [12].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 296 - 317

DOI: https://doi.org/10.1017/9781009002103.018 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Haslemo, T., Eikeseth, P. H., Tanum, L., et al. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol, 62, 1049–1053.Google Scholar

Bishara, D., Olofinjana, O., Sparshatt, A., et al. (2013). Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol, 33, 329–335.Google Scholar

Perry, P. J., Lund, B. C., Sanger, T., et al. (2001). Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol, 21, 14–20.Google Scholar

Lu, M. L., Wu, Y. X., Chen, C. H., et al. (2016). Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia. PLoS One, 11, e0148539.Google Scholar

Kelly, D. L., Richardson, C. M., Yang, Y., et al. (2006). Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol, 21, 393–398.Google Scholar

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.Google Scholar

Bigos, K. L., Pollock, B. G., Coley, K. C., et al. (2008). Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol, 48, 157–165.Google Scholar

Patel, M. X., Bowskill, S., Couchman, L., et al. (2011). Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999–2009. J Clin Psychopharmacol, 31, 411–417.Google Scholar

Meyer, J. M., Davis, V. G., Goff, D. C., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res, 101, 273–286.Google Scholar

Meyer, J. M. (2010). Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci, 4, 23–42.Google Scholar

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394, 939–951.Google Scholar

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar

McEvoy, J. P., Lieberman, J. A., Stroup, T. S., et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163, 600–610.Google Scholar

Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 7, 64–77.Google Scholar

Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar

Meltzer, H. Y., Bobo, W. V., Roy, A., et al. (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry, 69, 274–285.Google Scholar

Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789–796.Google Scholar

Samara, M. T., Dold, M., Gianatsi, M., et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73, 199–210.Google Scholar

Howes, O. D., McCutcheon, R., Agid, O., et al. (2017). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174, 216–229.Google Scholar

Conley, R. R., Tamminga, C. A., Bartko, J. J., et al. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry, 155, 914–920.Google Scholar

Conley, R. R., Tamminga, C. A., Kelly, D. L., et al. (1999). Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry, 46, 73–77.Google Scholar

Conley, R. R., Kelly, D. L., Richardson, C. M., et al. (2003). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol, 23, 668–671.Google Scholar

Kahn, R. S., Winter, van Rossum, I., Leucht, S., et al. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry, 5, 797–807.Google Scholar

Detke, H. C., McDonnell, D. P., Brunner, E., et al. (2010). Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry, 10,Google Scholar

Eli Lilly and Company (2020). Relprevv package insert. Indianapolis, IN.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Eli Lilly and Company (2020). Zyprexa Tablet, Intramuscular Injection package insert. Indianapolis, IN.Google Scholar

Soderberg, M. M. and Dahl, M. L. (2013). Pharmacogenetics of olanzapine metabolism. Pharmacogenomics, 14, 1319–1336.Google Scholar

Hiemke, C., Peled, A., Jabarin, M., et al. (2002). Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol, 22, 502–506.Google Scholar

Albers, L. J., Ozdemir, V., Marder, S. R., et al. (2005). Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol, 25, 170–174.Google Scholar

Khorassani, F., Kaufman, M., and Lopez, L. V. (2018). Supratherapeutic serum clozapine concentration after transition from traditional to electronic cigarettes. J Clin Psychopharmacol, 38, 391–392.Google Scholar

Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629–651.Google Scholar

Tveito, M., Smith, R. L., Høiseth, G., et al. (2019). The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections. J Clin Psychopharmacol, 39, 561–566.Google Scholar

Food and Drug Administration Center for Drug Evaluation and Research (2003). Olanzapine for injection pharmacology/clinical pharmacology and biopharmaceutics review.Google Scholar

McDonnell, D. P., Detke, H. C., Bergstrom, R. F., et al. (2010). Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry, 10, 45–54.Google Scholar

Heres, S., Kraemer, S., Bergstrom, R. F., et al. (2014). Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol, 29, 299–312.Google Scholar

Detke, H. C., Zhao, F., Garhyan, P., et al. (2011). Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol, 26, 35–42.Google Scholar

Fellows, L., Ahmad, F., Castle, D. J., et al. (2003). Investigation of target plasma concentration–effect relationships for olanzapine in schizophrenia. Ther Drug Monit, 25, 682–689.Google Scholar

Leucht, S., Kane, J. M., Kissling, W., et al. (2005). What does the PANSS mean? Schizophr Res, 79, 231–238.Google Scholar

Mamo, D., Kapur, S., Keshavan, M., et al. (2008). D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology, 33, 298–304.Google Scholar

Lataster, J., van Os, J., de Haan, L., et al. (2011). Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J Clin Psychiatry, 72, 1397–1404.Google Scholar

Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318–325.Google Scholar

Mizuno, Y., Bies, R. R., Remington, G., et al. (2012). Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry, 37, 182–187.Google Scholar

Giegling, I., Drago, A., Schafer, M., et al. (2010). Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res, 44, 487–492.Google Scholar

de Haan, L., van Bruggen, M., Lavalaye, J., et al. (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry, 160, 303–309.Google Scholar

Veselinovicć, T., Scharpenberg, M., Heinze, M., et al. (2019). Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: results from the randomized NeSSy Trial. J Clin Psychopharmacol, 39, 550–560.Google Scholar

Kelly, D. L., Conley, R. R., Richardson, C. M., et al. (2003). Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry, 15, 181–186.Google Scholar

Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar